Dr. Dilip Kumar Challa

International Journal of Cancer and Treatment

Molecular & Cellular Medicine

Name: Dr. Dilip Kumar Challa

Educational Qualification: PhD

Designation: Postdoctoral Research Associate at The University of Texas Southwestern Medical Center

Department: Molecular & Cellular Medicine

Texas A&M College of Medicine

Email: challa@medicine.tamhsc.edu

Research Interests: cellular and molecular immunology, neuroimmunology and tumor immunology.

Biography: Dr. Dilip Kumar Challa is a Postdoctoral Research Associate in department of Molecular & Cellular Medicine at The University of Texas Southwestern Medical Center, Dallas, Texas, USA. He completed his Doctor of Philosophy, Biomedical Engineering, Protein Engineering Track, The University of Texas Southwestern Medical Center in 2008-2016 and Master of Research, Biological Sciences (Field - Immunology), The University of Manchester, Manchester, UK in 2007-2008. Over 10 years of research experience in the field of immunology (cellular and molecular immunology, neuroimmunology and tumor immunology). Well trained to design, generate and test protein-based therapeutics/vaccines for inflammatory diseases and cancers. Authored multiple publications in reputed journals and a review article/book chapter in the fields of immunology and cancer. Trained and guided multiple postdoctoral scholars, graduate students and taught immunology and medical microbiology to medical students.

Deason, K., Troutman, T.D., Jain, A., Challa, D.K., Mandraju, R., Brewer, T., Ward, E.S. & Pasare, C. T cell intrinsic BCAP links IL-1R signaling to PI3K activation and regulates generation of pathogenic Th17 lineage cells. J Exp Med 215, 2413-2428 (2018).
Khare, P., Challa, D.K., Devanaboyina, S.C., Velmurugan, R., Hughes, S., Greenberg, B.M., Ober, R.J. & Ward, E.S. Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model. J Autoimmun 86, 104-115 (2018) [P.K. and D.K.C contributed equally to this study].
Devanaboyina, S.C., Khare, P., Challa, D.K., Ober, R.J. & Ward, E.S. Engineered clearing agents for the selective depletion of antigen-specific antibodies. Nat Commun 8, 15314 (2017).
Challa, D.K., Mi, W., Lo, S.T., Ober, R.J. & Ward, E.S. Antigen dynamics govern the induction of CD4 + T cell tolerance during autoimmunity. J Autoimmun 72, 84-94 (2016).
Velmurugan, R., Challa, D.K., Ram, S., Ober, R.J. & Ward, E.S. Macrophage-Mediate Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. Mol Cancer Ther 15, 1879-1889 (2016).
Swiercz, R., Chiguru, S., Tahmasbi, A., Ramezani, S.M., Hao, G.Y., Challa, D.K., Lewis, M.A., Kulkarni, P.V., Sun, X.K., Ober, R.J., Mason, R.P. & Ward, E.S. Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. J Nuc Med 55, 1204-1207 (2014).
Challa, D.K., Bussmeyer, U., Khan, T., Montoyo, H.P., Bansal, P., Ober, R.J. & Ward, E.S. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. mAbs 5, 655-659 (2013).
Bansal, P., Khan, T., Bussmeyer, U., Challa, D.K., Swiercz, R., Velmurugan, R., Ober, R.J. & Ward, E.S. The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed toward multiple epitopes in C57BL/6-immunized mice. J Immunol 191, 1091-1101 (2013).
Patel, D.A., Puig-Canto, A., Challa, D.K., Perez Montoyo, H., Ober, R.J. & Ward, E.S. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol 187, 1015-1022 (2011).

Review/Book chapter:

Challa, D.K., Velmurugan, R., Ober, R.J. & Sally Ward, E. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Curr Top Microbiol Immunol 382, 249-272 (2014) [Also published as chapter 12 in the book, Fc Receptors, Springer International Publishing].

Serial no:IIEBM0474

Download Certificate

Dr. Dilip Kumar Challa

International Journal of Cancer and Treatment

Molecular & Cellular Medicine

Guidelines

Quick Links

Subscribe